SNT 8.33% 3.9¢ syntara limited

Ann: Ceasing to be a substantial holder from Arix Bioscience, page-35

  1. 1,499 Posts.
    lightbulb Created with Sketch. 148
    Whats not to like 13m by the start of next year up to 15m re accusing there after cash inflow, 44m m/c and
    bone marrow/ cancer drug in stage 2 trials. 500m + market cap in the making easy
 
watchlist Created with Sketch. Add SNT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.